Friday, March 19, 2010
enGene CEO is 2010 Liberal Arts Alumni in Residence
Eric A. Adams
Contact for more information:
Wendy Knipe Bredhold Media Relations Specialist, News & Information Services 812/461-5259 Adams holds a bachelor's degree in chemistry with minors in German and business administration from USI and a Master of International Business Studies degree from the University of South Carolina. He received scholarships from the German Academic Exchange Service (DAAD) and from the Carl Duisberg Society for study abroad in Germany. His campus visit is sponsored by the Department of Modern and Classical Languages. In 2004, Adams was appointed CEO, president and director of enGene, Inc., a Vancouver, British Columbia-based biotechnology company developing an innovative therapeutic platform, called GEMS (Gut Endocrine-cell Modification System), which is targeted to induce normal cells in the intestinal tract to produce a wide range of therapeutic proteins (drugs) to treat a broad spectrum of diseases, including diabetes and inflammatory bowel disease, and also can act as a novel approach to vaccinations. He has more than 20 years of management experience in international business development, marketing, mergers and acquisitions, and sales in the pharmaceutical and related healthcare industries. In addition to his duties at enGene, Adams serves as a strategic advisor to Augurex Life Sciences Corp. and was recently elected chairman of the Emerging Company Advisory Board to BIOTECanada. He is a founder of Pracea Technologies Inc., a technology holding company, and is a member of USI's Pott College of Science and Engineering Board of Advisors. He is a frequent guest lecturer at the Simon Frasier University Management of Technology MBA program in Vancouver. Prior to enGene, Adams was a director of oncology marketing with QLT Inc. in Vancouver, director of International Marketing for severe burns products at Advanced Tissue Sciences, Inc. in San Diego, and the senior business development manager for Anti-Infectives at the international division of Abbott Laboratories, Inc. in Chicago, where he managed all ex-U.S. commercial activities related to Abbott's first $1B product, clarithromycin (BIAXIN). He also worked with Fresenius AG in Germany as a country manager for the U.S. and Italy, and as joint venture/acquisition team leader. For more information, call Dr. Silvia Anna Rode, chair of the Department of Modern and Classical Languages, at 812/465-7026. |
Copyright © 2013 University of Southern Indiana. All rights reserved.
